Analyst Ratings February 17, 2026

JPMorgan Opens Coverage of AeroVironment with Overweight Call and $320 Target

Analyst cites exposure to drones, counter-drone systems and space as drivers while warning of valuation and competition risks

By Priya Menon AVAV
JPMorgan Opens Coverage of AeroVironment with Overweight Call and $320 Target
AVAV

JPMorgan began coverage of AeroVironment (AVAV) with an Overweight rating and a $320 price objective, signaling roughly 31% upside from the stock's current trading level of $243.87. The bank points to AeroVironment's exposure to rapidly expanding defense niches - including drones, counter-drone systems and space - and projects mid-teens growth for the company. JPMorgan also highlighted a path to profitability anticipated by sell-side analysts, while noting valuation metrics and market competition as key concerns.

Key Points

  • JPMorgan initiated coverage of AeroVironment with an Overweight rating and a $320 price target, implying roughly 31% upside from the current $243.87 share price.
  • The bank expects mid-teens growth driven by exposure to drones, counter-drone systems and space, and projects the Autonomous Systems segment to grow about 14% annually through 2030; InvestingPro data shows nearly 80% revenue growth over the last twelve months.
  • AeroVironment secured a $75 million, five-year U.S. Air Force contract through its UES division for the FRESH program at Wright Patterson Air Force Base, reinforcing defense-related revenue opportunities.

JPMorgan has initiated coverage of AeroVironment (NASDAQ: AVAV) with an Overweight recommendation and set a price target at $320.00, which the firm says represents about a 31% increase versus the stock's prevailing price of $243.87.

The bank framed its call around AeroVironment's positioning across several defense-oriented technology segments. JPMorgan described the company as a diversified defense technology business with meaningful exposure to areas it regards as fast-growing, including unmanned aerial systems, counter-drone capabilities and activities tied to space.

Supporting that view, the note refers to data showing AeroVironment recorded nearly 80% revenue growth across the most recent twelve-month span. JPMorgan expects those demand drivers and the company's experience in defense markets to underpin mid-teens revenue expansion over time.

Within its coverage, JPMorgan singled out the firm's Autonomous Systems segment. That division, which includes drones and loitering munitions that have seen increased relevance in recent conflicts, is modeled to expand at approximately 14% per year through 2030 under the bank's assumptions.

The report also addresses AeroVironment's recent profitability profile. While the company was not profitable over the last twelve months, InvestingPro Tips referenced in the coverage indicate analysts on the street expect AeroVironment to return to profitability during the current year.

JPMorgan pointed to Department of Defense initiatives to broaden the industrial base and adopt more commercially oriented approaches as potential tailwinds for AeroVironment. The firm noted AeroVironment's lengthy experience in defense contracting as a relevant qualification if such policy shifts accelerate procurement from a wider set of suppliers.

At the same time, JPMorgan cautioned that the competitive dynamics in these markets remain a notable risk. The brokerage highlighted the sector's intensity and said competition could constrain outcomes despite strong demand trends.

Market and valuation indicators were also flagged. The stock declined about 7.37% over the last week, according to the coverage, and InvestingPro Fair Value metrics suggest the shares may be trading above intrinsic value. JPMorgan's note points to a high enterprise-value-to-EBITDA multiple of 117.4 as a signal of elevated valuation.

Separately, the company has won a $75 million contract with the U.S. Air Force via its UES division. That five-year award will support research on advanced biotechnology and smart materials as part of the Functional Responsive Experimentation for Systems and Humans, or FRESH, program, with work to be conducted at Wright Patterson Air Force Base in Ohio.

Other analyst commentary referenced in the coverage includes Citizens' maintenance of a Market Outperform rating and a $400.00 price target for AeroVironment, a firm that cited strengthening U.S. and global defense priorities. The broader drone market was noted as projecting to reach approximately $53.45 billion by 2026, which the report linked to technology advances and wider adoption across sectors.

The combination of a new sell-side initiation, a recent DoD contract, and multi-analyst coverage highlights the attention on AeroVironment as it navigates growth opportunities and valuation scrutiny.


Context and next steps

Investors and market watchers will likely monitor the company's execution against projected Autonomous Systems growth, progress toward profitability this year as anticipated by analysts, and any further contract awards that demonstrate traction with defense customers.

Risks

  • Intense competition in drones and related defense markets could limit market share gains and margins, affecting aerospace and defense sector participants.
  • Valuation appears elevated by some measures, with a reported EV/EBITDA multiple of 117.4 and InvestingPro Fair Value metrics suggesting the shares may be overvalued, introducing market and investor risk.
  • Recent share-price volatility, including a 7.37% decline over the last week, underlines potential stock market sensitivity to news flow and execution risks in the industrials and defense technology sectors.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026